Novartis AG’s $9.7bn move to acquire The Medicines Company and its first-in-class siRNA cholesterol lowering drug, inclisiran, has generated a new buzz around novel cardiovascular medicine companies and other M&A targets.
Unveiled on 24 November, the deal has set the rumor mill whirring on who might be next on big pharma’s M&A wish list, and has lifted